Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Personalized medicine in transplantation therapy].

Rinsho byori. The Japanese journal of clinical pathology - 1 May 2013

Nakatani Kaname

Abstract excerpt

Personalized medicine based on pharmacogenomics is being developed at the clinical stage. Various evidence is accumulating in transplantation therapy. Tacrolimus, a calcineurin inhibitor, is usually used for immunosuppressive therapy after transplantation. Tacrolimus is mainly metabolized by cytochrome P450 isozymes, CYP3A4 and CYP3A5, expressed in the intestine as well as in the liver. Recent studies of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genotype
Share to Immunosuppressive Agents
Share to Organ Transplantation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Precision Medicine

Share to Tacrolimus

Share to Treatment Outcome

Source

Identifiers

PMID: 23947183

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Personalized medicine in transplantation therapy].PMID 23947183Read ↗

Personalized immunosuppression after kidney transplantation.Semantic proximity Read ↗

CYP3A5 Polymorphism in Renal Transplantation: A Key to Personalized Immunosuppression.Semantic proximity Read ↗

[Pharmacogenetics of tacrolimus: from bench to bedside?].Semantic proximity Read ↗

Pharmacogenetics in solid organ transplantation: current status and future directions.Semantic proximity Read ↗

Genotype-guided tacrolimus dosing: The role of CYP3A5 polymorphisms in optimising kidney transplant immunosuppression in BhutanSemantic proximity Read ↗

Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver TransplantationSemantic proximity Read ↗

The Prognostic Role of CYP Enzyme in Kidney Transplantation: A Single Centre Experience.Semantic proximity Read ↗

Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives.Semantic proximity Read ↗

The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living-donor Egyptian kidney transplanted patients.Semantic proximity Read ↗

CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis.Semantic proximity Read ↗

Effect of CYP3A5*1 expression on tacrolimus required dose after liver transplantation: A systematic review and meta-analysis.Semantic proximity Read ↗

Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic considerations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.